Haihong Pu

Harbin, 150081, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Tumor immune organoids in immunotherapy resistance and drug screening.

Tumor immune organoids in immunotherapy resistance and drug screening.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: September 04, 2025

Disease burden of lung cancer attributable to metabolic and behavioral risks in China and globally from 1990 to 2021.

Disease burden of lung cancer attributable to metabolic and behavioral risks in China and globally from 1990 to 2021.

Journal: BMC public health

Published: November 01, 2024

Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer.

Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer.

Journal: Critical reviews in oncology/hematology

Published: June 06, 2024

Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338-3p/RAB1B axis.

Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338-3p/RAB1B axis.

Journal: Pathology, research and practice

Published: December 16, 2022

CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma.

CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma.

Journal: Frontiers in immunology

Published: November 01, 2021

MiR-342-3p inhibits LCSC oncogenicity and cell stemness through HDAC7/PTEN axis.

MiR-342-3p inhibits LCSC oncogenicity and cell stemness through HDAC7/PTEN axis.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Published: June 15, 2021

Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.

Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.

Journal: Frontiers in oncology

Published: July 22, 2020

An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma.

An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma.

Journal: Frontiers in oncology

Published: April 01, 2019

Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms.

Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms.

Journal: Journal of Cancer

Published: March 19, 2018

Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma.

Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma.

Journal: Oncotarget

Published: March 14, 2017

VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer.

VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer.

Journal: Pathology oncology research : POR

Published: September 19, 2016

Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.

Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.

Journal: Oncotarget

Published: July 04, 2016

Showing 1-12 of 14

Last Updated: 09/26/2026